WNK2 and ovarian cancer: Co-treatment consisting of formononetin with synthetic inhibitors for ovarian cancer, such as LY294002 (PI3K inhibitor) or U0126 [mitogen activated protein kinase kinase (MEK) inhibitor], further prevented the proliferative effects on ovarian cancer cells (ES2 and OV90), thus increasing the occurrence of apoptosis in both cell lines [99].